EV/EBIT společnosti AC Immune SA
Jaká je hodnota metriky EV/EBIT společnosti AC Immune SA?
Hodnota metriky EV/EBIT společnosti AC Immune SA je N/A
Jaká je definice metriky EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností AC Immune SA
Čemu se věnuje společnost AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Firmy s metrikou ev/ebit podobnou společnosti AC Immune SA
- Hodnota metriky EV/EBIT společnosti Nephros je N/A
- Hodnota metriky EV/EBIT společnosti Nephros je N/A
- Hodnota metriky EV/EBIT společnosti Nephros je N/A
- Hodnota metriky EV/EBIT společnosti Conifer je N/A
- Hodnota metriky EV/EBIT společnosti National je N/A
- Hodnota metriky EV/EBIT společnosti Tattooed Chef je N/A
- Hodnota metriky EV/EBIT společnosti AC Immune SA je N/A
- Hodnota metriky EV/EBIT společnosti DC Two je N/A
- Hodnota metriky EV/EBIT společnosti On Track Innovations je N/A
- Hodnota metriky EV/EBIT společnosti Troy Resources je N/A
- Hodnota metriky EV/EBIT společnosti Evofem Biosciences Inc je N/A
- Hodnota metriky EV/EBIT společnosti Osirium Technologies PLC je N/A
- Hodnota metriky EV/EBIT společnosti Khiron Life Sciences je N/A